Albert David Ltd manufactures and sells pharmaceutical formulations, infusion solutions, and active ingredients, primarily focused on regenerative medicine and wound care through its flagship human placental extract brand.
The company possesses a narrow moat derived from its long-standing clinical authority and proprietary research in human placental extract (Placentrex), which accounts for over 30% of revenue. However, stagnant revenue growth (0.7% CAGR) and low average ROE (11.8%) suggest that while the brand is entrenched, it lacks significant pricing power or expansionary leverage.
Capital allocation is conservative but uninspiring; the company maintains a very low debt-to-equity ratio (0.07) and pays consistent dividends, yet heavy reinvestment in field force expansion and R&D has not yet translated into meaningful top-line growth.
The investment collapsed as the company's stagnant revenue growth finally turned negative, proving that the 'clinical authority' of Placentrex was a wasting asset rather than a growth engine. Management's repeated attempts to buy growth through field force expansion backfired, as the increased overhead permanently suppressed margins while failing to capture new market share. The revolving door in the CEO's office led to strategic drift, and the capital that should have been returned to shareholders was instead consumed by rising operational costs and related-party transactions, leaving the company a value trap with no path to scale.
RichFakir rates Albert David Ltd's business quality as poor — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Albert David Ltd is trading about 24% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Albert David Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Albert David Ltd's fair value is about ₹618 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →